POTESTIO, LUCA
POTESTIO, LUCA
DIPARTIMENTO DI SCIENZE MEDICHE TRASLAZIONALI
Allergic contact dermatitis probably due to brimonidine tartrate in eyedrops
2021 Napolitano, Maddalena; Potestio, Luca; Castagliola, Ciro; Fabbrocini, Gabriella; Patruno, Cataldo
Tildrakizumab: a new therapeutic option for erythrodermic psoriasis?
2021 Megna, M.; Potestio, L.; Fabbrocini, G.; Cinelli, E.
Alcohol flushing during dupilumab therapy: an emerging adverse event
2021 Napolitano, Maddalena; Potestio, Luca; Fabbrocini, Gabriella; Patruno, Cataldo
Scabies outbreak during COVID-19: an Italian experience
2021 De Lucia, M.; Potestio, L.; Costanzo, L.; Fabbrocini, G.; Gallo, L.
Dupilumab effectiveness for the treatment of patients with concomitant atopic dermatitis and chronic rhinosinusitis with nasal polyposis
2021 Napolitano, Maddalena; Maffei, Marianna; Patruno, Cataldo; Leone, Carlo Antonio; Guida, Adriana; Potestio, Luca; Scalvenzi, Massimiliano; Fabbrocini, Gabriella
Reply to "Psoriasis exacerbation after Covid-19 vaccination: report of 14 cases from a single center" by Sotiriou E et al
2021 Megna, M; Potestio, L; Gallo, L; Caiazzo, G; Ruggiero, A; Fabbrocini, G
New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge?
2021 Megna, Matteo; Ocampo-Garza, Sonia Sofia; Potestio, Luca; Fontanella, Giuseppina; Gallo, Lucia; Cacciapuoti, Sara; Ruggiero, Angelo; Fabbrocini, Gabriella
Letter to the editor regarding article "Yalici-Armagan B, Tabak GH, Dogan-Gunaydin S, Gulseren D, Akdogan N, Atakan N. Treatment of psoriasis with biologics in the early COVID-19 pandemic: A study examining patient attitudes toward the treatment and disease course. J Cosmet Dermatol. 2021;00:1-5"
2021 Potestio, Luca; Camela, Elisa; Fabbrocini, Gabriella; Megna, Matteo
Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma
2021 Villani, A.; Ocampo-Garza, S. S.; Potestio, L.; Fabbrocini, G.; Ocampo-Candiani, J.; Ocampo-Garza, J.; Scalvenzi, M.
Letter to the editor regarding article "Oguz Topal I, Kara Polat A, Zindancı İ, et al. Adherence to systemic therapy in patients with psoriasis during the COVID-19 pandemic: A multicenter study. J Cosmet Dermatol. 2021;10.1111/jocd.14610."
2022 Potestio, Luca; Camela, Elisa; Tajani, Andrea; Fabbrocini, Gabriella; Megna, Matteo
Dermatophytid evaluated by in vivo reflectance confocal microscopy: a new approach?
2022 Potestio, Luca; Villani, Alessia; Ocampo‐garza, Sonia Sofia; Evangelista, Emanuela; De Lucia, Mario; Costanzo, Luca; Camela, Elisa; Fabbrocini, Gabriella; Gallo, Lucia
Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study
2022 Megna, Matteo; Potestio, Luca; Ruggiero, Angelo; Camela, Elisa; Fabbrocini, Gabriella
Letter to the editor submitted in response to "Should the presence of psoriatic arthritis change how we manage psoriasis?"
2022 Megna, Matteo; Ocampo-Garza, Sonia Sofia; Fabbrocini, Gabriella; Potestio, Luca
Atopic dermatitis exacerbation after Covid‐19 vaccination in Dupilumab‐treated patients
2022 Potestio, L.; Napolitano, M.; Bennardo, L.; Fabbrocini, G.; Patruno, C.
Clinical, trichoscopic and in vivo reflectance confocal microscopy evaluation of alopecia areata in atopic dermatitis patients treated with dupilumab
2022 Napolitano, M.; Cantelli, M.; Potestio, L.; Ocampo‐garza, S. S.; Vastarella, M.; Nappa, P.; Scalvenzi, M.; Fabbrocini, G.; Patruno, C.
Acrodermatitis continua of Hallopeau: is apremilast an efficacious treatment option?
2022 Megna, Matteo; Potestio, Luca; Caprio, Nicola; Tajani, Andrea; Fabbrocini, Gabriella; Annunziata, Alberto
Teledermatology: a useful tool also after Covid-19 era?
2022 Megna, Matteo; Camela, Elisa; Villani, Alessia; Tajani, Andrea; Fabbrocini, Gabriella; Potestio, Luca
Teledermatology and Inflammatory Skin Conditions during COVID-19 Era: New Perspectives and Applications
2022 Marasca, C.; Annunziata, M. C.; Camela, E.; Di Guida, A.; Fornaro, L.; Megna, M.; Napolitano, M.; Patruno, C.; Potestio, L.; Fabbrocini, G.
Risankizumab treatment in psoriasis patients who failed anti-IL17: a 52-week real-life study
2022 Megna, Matteo; Potestio, Luca; Ruggiero, Angelo; Camela, Elisa; Fabbrocini, Gabriella
Letter to the editor regarding article "Gu L, Diaz SM, Lipner SR. Retrospective study of acne telemedicine and in-person visits at an academic center during the COVID-19 pandemic. J Cosmet Dermatol. 2022;21(1):36-38."
2022 Potestio, Luca; Fabbrocini, Gabriella; Villani, Alessia
| Titolo | Tipologia | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|---|
| Allergic contact dermatitis probably due to brimonidine tartrate in eyedrops | 1.1 Articolo in rivista | 2021 | Napolitano, Maddalena; Potestio, Luca; Castagliola, Ciro; Fabbrocini, Gabriella; Patruno, Cataldo | |
| Tildrakizumab: a new therapeutic option for erythrodermic psoriasis? | 1.1 Articolo in rivista | 2021 | Megna, M.; Potestio, L.; Fabbrocini, G.; Cinelli, E. | |
| Alcohol flushing during dupilumab therapy: an emerging adverse event | 1.1 Articolo in rivista | 2021 | Napolitano, Maddalena; Potestio, Luca; Fabbrocini, Gabriella; Patruno, Cataldo | |
| Scabies outbreak during COVID-19: an Italian experience | 1.1 Articolo in rivista | 2021 | De Lucia, M.; Potestio, L.; Costanzo, L.; Fabbrocini, G.; Gallo, L. | |
| Dupilumab effectiveness for the treatment of patients with concomitant atopic dermatitis and chronic rhinosinusitis with nasal polyposis | 1.1 Articolo in rivista | 2021 | Napolitano, Maddalena; Maffei, Marianna; Patruno, Cataldo; Leone, Carlo Antonio; Guida, Adriana; Potestio, Luca; Scalvenzi, Massimiliano; Fabbrocini, Gabriella | |
| Reply to "Psoriasis exacerbation after Covid-19 vaccination: report of 14 cases from a single center" by Sotiriou E et al | 1.7 Commento, erratum, replica e simili | 2021 | Megna, M; Potestio, L; Gallo, L; Caiazzo, G; Ruggiero, A; Fabbrocini, G | |
| New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge? | 1.1 Articolo in rivista | 2021 | Megna, Matteo; Ocampo-Garza, Sonia Sofia; Potestio, Luca; Fontanella, Giuseppina; Gallo, Lucia; Cacciapuoti, Sara; Ruggiero, Angelo; Fabbrocini, Gabriella | |
| Letter to the editor regarding article "Yalici-Armagan B, Tabak GH, Dogan-Gunaydin S, Gulseren D, Akdogan N, Atakan N. Treatment of psoriasis with biologics in the early COVID-19 pandemic: A study examining patient attitudes toward the treatment and disease course. J Cosmet Dermatol. 2021;00:1-5" | 1.1 Articolo in rivista | 2021 | Potestio, Luca; Camela, Elisa; Fabbrocini, Gabriella; Megna, Matteo | |
| Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma | 1.1 Articolo in rivista | 2021 | Villani, A.; Ocampo-Garza, S. S.; Potestio, L.; Fabbrocini, G.; Ocampo-Candiani, J.; Ocampo-Garza, J.; Scalvenzi, M. | |
| Letter to the editor regarding article "Oguz Topal I, Kara Polat A, Zindancı İ, et al. Adherence to systemic therapy in patients with psoriasis during the COVID-19 pandemic: A multicenter study. J Cosmet Dermatol. 2021;10.1111/jocd.14610." | 1.1 Articolo in rivista | 2022 | Potestio, Luca; Camela, Elisa; Tajani, Andrea; Fabbrocini, Gabriella; Megna, Matteo | |
| Dermatophytid evaluated by in vivo reflectance confocal microscopy: a new approach? | 1.1 Articolo in rivista | 2022 | Potestio, Luca; Villani, Alessia; Ocampo‐garza, Sonia Sofia; Evangelista, Emanuela; De Lucia, Mario; Costanzo, Luca; Camela, Elisa; Fabbrocini, Gabriella; Gallo, Lucia | |
| Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study | 1.1 Articolo in rivista | 2022 | Megna, Matteo; Potestio, Luca; Ruggiero, Angelo; Camela, Elisa; Fabbrocini, Gabriella | |
| Letter to the editor submitted in response to "Should the presence of psoriatic arthritis change how we manage psoriasis?" | 1.1 Articolo in rivista | 2022 | Megna, Matteo; Ocampo-Garza, Sonia Sofia; Fabbrocini, Gabriella; Potestio, Luca | |
| Atopic dermatitis exacerbation after Covid‐19 vaccination in Dupilumab‐treated patients | 1.1 Articolo in rivista | 2022 | Potestio, L.; Napolitano, M.; Bennardo, L.; Fabbrocini, G.; Patruno, C. | |
| Clinical, trichoscopic and in vivo reflectance confocal microscopy evaluation of alopecia areata in atopic dermatitis patients treated with dupilumab | 1.1 Articolo in rivista | 2022 | Napolitano, M.; Cantelli, M.; Potestio, L.; Ocampo‐garza, S. S.; Vastarella, M.; Nappa, P.; Scalvenzi, M.; Fabbrocini, G.; Patruno, C. | |
| Acrodermatitis continua of Hallopeau: is apremilast an efficacious treatment option? | 1.1 Articolo in rivista | 2022 | Megna, Matteo; Potestio, Luca; Caprio, Nicola; Tajani, Andrea; Fabbrocini, Gabriella; Annunziata, Alberto | |
| Teledermatology: a useful tool also after Covid-19 era? | 1.1 Articolo in rivista | 2022 | Megna, Matteo; Camela, Elisa; Villani, Alessia; Tajani, Andrea; Fabbrocini, Gabriella; Potestio, Luca | |
| Teledermatology and Inflammatory Skin Conditions during COVID-19 Era: New Perspectives and Applications | 1.1 Articolo in rivista | 2022 | Marasca, C.; Annunziata, M. C.; Camela, E.; Di Guida, A.; Fornaro, L.; Megna, M.; Napolitano, M.; Patruno, C.; Potestio, L.; Fabbrocini, G. | |
| Risankizumab treatment in psoriasis patients who failed anti-IL17: a 52-week real-life study | 1.1 Articolo in rivista | 2022 | Megna, Matteo; Potestio, Luca; Ruggiero, Angelo; Camela, Elisa; Fabbrocini, Gabriella | |
| Letter to the editor regarding article "Gu L, Diaz SM, Lipner SR. Retrospective study of acne telemedicine and in-person visits at an academic center during the COVID-19 pandemic. J Cosmet Dermatol. 2022;21(1):36-38." | 1.1 Articolo in rivista | 2022 | Potestio, Luca; Fabbrocini, Gabriella; Villani, Alessia |